Archive for the ‘Treatment’ Category

A Quick Tour of the New IDSA Lyme Disease Guidelines

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29231613?

A Quick Tour of the New (IDSA) Lyme Disease Guideline

JUN 20, 2021 — 

Please see the email below sent to Dr. Paul Auwaerter of the Infectious Diseases Society of America.

FYI…per the link below:

Pending approval by the court, the TORREY v. IDSA is now an anti-trust lawsuit against a single defendant: The Infectious Diseases Society of America.

https://www.lymedisease.org/idsa-lyme-lawsuit-update-pfeiffer/

———- Original Message ———-

From: CARL TUTTLE <runagain@comcast.net>
To: “pauwaert@jhmi.edu” <pauwaert@jhmi.edu>, “alexa011@mc.duke.edu” <alexa011@mc.duke.edu>, “thomas.fekete@temple.edu” <thomas.fekete@temple.edu>, “editor2@webmd.net” <editor2@webmd.net>
Cc: All members of the NH Lyme Study Commission, “governorsununu@nh.gov” <governorsununu@nh.gov>
Date: 06/19/2021 12:28 PM
Subject: A Quick Tour of the New Lyme Disease Guideline

MEDSCAPE COMMENTARY
 
A Quick Tour of the New Lyme Disease Guideline
https://www.medscape.com/viewarticle/951589
Paul G. Auwaerter, MD

June 14, 2021

Excerpt:

“Of importance, the guideline goes out of its way to cite the lack of evidence for performing Lyme disease tests, specifically routine testing in cases where there’s no evidence or link to Lyme disease. Examples include someone who is asymptomatic after a tick bite, even when they have a neurologic condition such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, dementia, or any kind of new-onset seizures or psychiatric illness. In children, behavioral and developmental disorders don’t warrant assessing a Lyme disease serology.

June 19, 2021

The IDSA Foundation
1300 Wilson Boulevard Suite 300
Arlington, VA 22209
Attn:  Paul Auwaerter, vice chair of the IDSA Foundation

Dear Dr. Auwaerter,

In reference to your recommendation not to test for Lyme disease in children with behavioral and developmental disorders are you aware of the following article?

Study detects tick-borne illness in teens hospitalized for depression
https://www.lymedisease.org/hospitalized-teens-lyme-depression/

Ten patients were diagnosed with DSM-5 Major Depressive Disorder, seven were additionally diagnosed with Generalized Anxiety Disorder, and three had made serious suicide attempts.

Ten adolescents picked at random with mental illness severe enough that they required institutionalization—nine of them had evidence of tick-borne infections and nine had evidence of autoimmune encephalitis.

____________________________________

Dr. Auwaerter… It sounds to me like your recommendation “not to test for Lyme” might not be sound advice after all which begs the question; how many other patients currently in the healthcare system being treated for neurologic conditions are actually dealing with untreated Lyme disease and/or co-infections?

A response to this inquiry is requested.
Respectfully submitted,

Carl Tuttle
Hudson, NH

Member of Governor Chris Sununu’s Lyme Disease Study Commission
http://www.gencourt.state.nh.us/statstudcomm/details.aspx?id=1515&rbl=1&txtbillnumber=hb490
Cc: All members of the NH Lyme Disease Study Commission

THOMAS FEKETE, M.D., FIDSA CHAIR of the IDSA Foundation

Barbara D. Alexander, MD, MHS, FIDSA, President IDSA

A Quick Tour of the New Lyme Disease Guideline
This transcript has been edited for clarity. Hello. This is Paul Auwaerter for Medscape Infectious Diseases, speaking from Johns Hopkins…

Eva Sapi, Lyme Disease Research Group on Antibiotic Resistance of Borrelia burgdorferi

Public Tick IPM WG Call Notes – 6.9.2021  Go here for Dr. Sapi’s presentation

A recording of this webinar is available by visiting this link: https://photos.app.goo.gl/vrvbX7HbhcVkrnq37

Dr. Eva Sapi teaches Biology at the University of New Haven and has a research group that studies Borrelia burgdorferi.

Lyme disease numbers are going up with approximately 476,000 of Americans diagnosed and treated for Lyme disease from CDC surveillance data covering 2010-2018.

In vitro and clinical data observing the efficacy of antibiotics against Borrelia burgdorferi found that antibiotics, in some cases, do not work against Borrelia burgdorferi. In the mid-90s, in vivo studies found evidence that antibiotics such as tetracycline, erythromycin or doxycycline, failed to eradicate acute Borrelia burgdorferi infections. Studies turned to a stronger antibiotic, ceftriaxone. These studies also showed antibiotic resistance of Borrelia burgdorferi. These results led to the question of why Borrelia burgdorferi cannot be killed and if any other form(s) exist that are resistant to therapy.

___________________

**Comment**

Very interesting webinar on the persistence of Lyme.

Sapi is also known for her in vitro work with Stevia. When I inquired about dosages, she stated those have not been determined. Dr. Horowitz and many other LLMD’s are using stevia as a biofilm and cyst form disruptor. The new kid on the block is liposomal oregano oil (some also use clove and cinnamon or a combination of the three) based on Dr. Zhang’s work.) When I inquired about these, she stated that these same doctors are also finding results using them but results are anecdotal. Dr. Phillips mentions it in his book “Chronic.” Dr. Ross also mentions it.

I’ve previously used cinnamon, clove, and oregano essential oils (EO’s) put with black seed oil in capsules. When I questioned herbalist Greg Lee on dosage, he agreed with my treatment of a total of 6 drops of EO’s taken twice a day. I never herxed or noticed any recognizable results on this treatment and relapsed on it. Lee spoke about liposomal oils years ago at an ILADS convention, but they were hard to find at the time.

I am currently using the liposomal form of oregano as part of my Bartonella treatment with (Rifampin/Clarithromycin). I’m hoping this combination works and has lasting results. The brand “Doctor Inspired Formulations” within the link can be found cheaper elsewhere, but they are all pretty expensive. I do not have a financial affiliation with anyone. Please note the other liposomal forms they create as well.

Study Shows HCQ & Azithromycin Improved Survival by over 100% in Ventilated COVID Patients

https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1

Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic

Leon G. Smith, Nicolas Mendoza, David Dobesh, Stephen M. Smith
 

Abstract

Introduction This observational study looked at 255 COVID19 patients who required invasive mechanical ventilation (IMV) during the first two months of the US pandemic. Through comprehensive, longitudinal evaluation and new consideration of all the data, we were able to better describe and understand factors affecting outcome after intubation.

Methods All vital signs, laboratory values, and medication administrations (time, date, dose, and route) were collected and organized. Further, each patient’s prior medical records, including PBM data and available ECG, were reviewed by a physician. These data were incorporated into time-series database for statistical analysis.

Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were:

  • hypertension, (63.5%)
  • diabetes (59.2%)
  • obesity (50.4%)

Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold.

Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%.

QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.

Discussion This detailed approach gives us better understanding of risk factors, prognostic indicators, and outcomes of Covid patients needing IMV. Few variables were related to outcome. By considering more factors and using new methods, we found that when increased doses of co-administered HCQ and AZM were associated with >100% increase in survival. Comparison of absolute with weight-adjusted cumulative doses proves administration ≥80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring Covid patients by over 100%. According to our data, HCQ is not associated with prolongation.

Studies, which reported QTc prolongation secondary to HCQ, need to be re-evaluated more stringently and with controls.

The weight ranges of Covid patient cohorts are substantially greater than those of most antibiotic RCTs. Future clinical trials need to consider the weight variance of hospitalized Covid patients and need to study therapeutics more thoughtfully.

___________________

**Comment**

We were told from the beginning by doctors treating COVID patients that HCQ, azithromycin, and zinc works.  Unfortunately, this beneficial treatment, along with Ivermectin and others was smeared and censored by public health ‘authorities’ and main stream media (along with the doctors advocating them).  We were also told all of a sudden HCQ is dangerous (QTc prolongation) despite decades of safe usage.  Then the ‘powers that be’ even published a faulty study on it that had to be retracted.  A doctor took the time to really sift through the burgeoning, government funded HCQ studies and discovered the dosages given were enough to kill a horse.

The false narrative that there aren’t any effective treatments for COVID continues to this day so everyone will remain fearful and get the experimental, fast-tracked COVID jab despite thousands of reports of death and severe adverse reactions – which continue to mount.  Vaccine experts also continue to warn about the dangerous spike protein in the injections that circulate in the body causing deadly reactions. Virologists are warning that mass vaccination is causing mutant or variant strains to develop which will be more severe and more resistant to vaccines.

We’ve been warned about antibody dependent enhancement (ADE) or pathogenic priming which is currently being seen in countries undertaking mass vaccination:

Montagnier states,

“You see it in each country, it’s the same: the curve of vaccination is followed by the curve of deaths.  I’m following this closely and I a doing experiments at the Institute with patients who became sick with Corona after being vaccinated.”

Which brings us to the topic of the mis-leading term, “break-through” cases, or those who become ill AFTER vaccination, proving these injections don’t stop you from contracting COVID or even dying from it.

A group of doctors wrote a paper which couldn’t be more clear:

The experimental vaccines are needless, ineffective and dangerous.” 

Lyme Disease: The Silent Pandemic

https://www.drtaniadempsey.com/post/lyme-disease-the-silent-pandemic

Dr. Tania Dempsey

Lyme Disease: The Silent Pandemic

Updated: Jul 21, 2020

Lyme disease is the other pandemic that has been ignored. Tick season and an increase in Lyme disease cases in the next few months will be difficult to discern from COVID-19. Plus, many hospitals have reported running out of doxycycline during COVID-19, which is the number one medication that is used for lyme disease… All of this will skyrocket cases of lyme and make it even harder to treat and diagnose.

· Lyme Disease is a silent pandemic

· Estimates suggest that over 1 million people suffer from chronic Lyme disease

While the county races to find a cure for COVID-19 in record time, lyme disease treatment and testing lag behind in comparison.

We are living through what many would consider our first real pandemic in our lifetime. However, I would argue that we have been in the midst of a global epidemic of Lyme disease for over twenty years.

Lyme disease has been underreported and misunderstood since the first case was diagnosed in 1975 in Old Lyme, CT. While we watch the rapid scientific discoveries come to light regarding COVID-19, I become more aware of the paucity of new data for Lyme disease.

In a matter of months, we have seen a rapid response to the development of tests for COVID-19 PCR and antibodies (with room for improvement), but in the 39 years since the bacteria that causes Lyme disease (Borrelia burgdorferi) was identified, we are still incredibly behind in diagnostic testing, as well as treatment strategies and prevention.

While we are engaged in the battle with one infectious disease, we have the opportunity to reflect on other infectious diseases, specifically Lyme disease and co-infections, such as Babesia, Bartonella and other tick-borne infections. Tick-borne infections are on the rise and increasing exponentially with some research indicating that there are approximately 300,000 new cases of Lyme disease each year.

This increase in cases is due to a number of factors. The tick population, as a whole, has exploded as a result of global temperature increases, which in the last few years has led to shorter winters that allow adult ticks to continue to thrive. In addition, ticks have expanded their range as their hosts, the white-footed mouse and deer infiltrate into more heavily populated areas.

Every year, as the number of ticks increase, so do the number of diseases that each tick can carry. Research from July to October 2019 in upstate New York showed that 32% of the ticks carried at least one infection, primarily Lyme disease. This number was higher than expected. 3% of the ticks also carried multiple diseases or co-infections.

Each tick-borne infection carries their own risks. Some are deadly, like Powassan, some present acutely but are easily treated if found early, such as Ehrlichiosis, and others vary dramatically in their presentation and ease of treatment. The reality is that with Lyme disease, many patients that are infected are diagnosed and treated early, can make a full recovery.

However, about 10 to 20% of patients may have persistent symptoms that become chronic. There is very little data about chronic lyme disease and many believe that these patients have PTLDS (post-treatment Lyme disease syndrome), which implies that the patient’s symptoms are due to something other than continued infection. Similarly, COVID-19 seems to cause persistent or relapsing symptoms in some patients long after the initial infection.

Understanding our immune system’s response to one infection might, in fact, benefit our understanding of others.

People are justifiably fearful about getting infected with COVID-19. It’s a new virus. We don’t know that much about it, but it seems that every day we slowly gain insight into how this virus works. What is most astonishing is the tremendous variability in presentations that patients with COVID-19 have. No two patients are alike.

We are seeing some patients with mild respiratory symptoms and others with severe symptoms requiring intubation. We are seeing patients present with large blood clots, like pulmonary embolisms or strokes. We are seeing patients with other vascular symptoms, such as “COVID toes.” Some patients have gastrointestinal symptoms. Fever was initially thought to be a hallmark feature of the viral infection, but the data shows that less than 50% of patients with COVID-19 develop a fever at presentation.

The medical field is starting to understand the importance of keeping an open mind and that “no two patients are alike.” This approach sounds incredibly familiar to those of us who treat patients with Lyme disease, but unfortunately, it has not necessarily been embraced by the medical establishment until now.

Lyme disease is similarly inconsistent.

Lyme can present early with classic symptoms of a bull’s eye rash, fever, headache and muscle aches but less than 50% of patients present in this manner and even when there is a rash it often doesn’t resemble a bull’s eye. Many patients don’t even remember getting bitten by a tick, so Lyme disease can go undetected during the early stages until it infects major organs. It can damage the heart, the nervous system, joints, and many other parts of the body.

Lyme is a multisystemic disease with great variability that is not often recognized by doctors which, unfortunately, leaves many patients without an accurate diagnosis and without proper treatment. COVID-19 also causes multisystemic inflammation, but this phenomenon has been well accepted by medical professionals.

You don’t see COVID-19 patients being stigmatized as Lyme patients often are. Lyme disease can cause debilitating symptoms such as fatigue, headaches, joint pain, and brain fog, and yet on the outside these patients can look completely normal. This leads those around them, including their doctors to doubt the severity of their illness. They may be labeled as “crazy.” We often refer to diseases like Lyme as invisible illnesses, because they are invisible on the outside but devastating to the patient on the inside.

This is the spring when the trees are blooming, the grass is growing, and the ticks are out in droves, raising the concern for the potential of a significant rise in Lyme disease cases. This year might, in fact, be worse than previous years due to the relatively warm winter, which allowed ticks to continue thriving. I believe SARS-COV-2 might play an even larger role in the potential increased incidence of Lyme disease. While we remain isolated at home and practice social distancing, the beautiful weather will send more people outdoors. Some will stay in their backyard and others will venture out onto hiking trails. Some have new puppies or dogs that need to be exercised outdoors and others will embrace growing their own food and gardening.

What precautions are people taking before going outside? I know many will don masks in case they run into other people. I think some people will remember to put on sunscreen or wear a hat to prevent a sunburn.

How many people will remember to protect themselves from insect and tick bites with insect repellant?

How many will remember to do tick checks when they come indoors?

I fear that our shift towards COVID-19 prevention may shift the focus away from Lyme disease prevention. This could lead to an escalation in tick bites and new infections.

There is real danger from getting bitten by a tick. There is, no doubt, real danger from getting infected with SARS-COV-2, too. Both pose serious risks and both present challenges to treatment. For months preceding the pandemic, we had been seeing an increasing number of drug shortages. Certainly, since the pandemic, this situation is worse. As soon as a drug is found to have activity against COVID-19, people begin to stock-pile and the supply dwindles quickly.

Unfortunately, some of these drugs that are in limited supply are used as first and second-line treatment against Lyme and co-infections, such as doxycycline and hydroxychloroquine. Lyme disease that is not adequately treated can leave long lasting, chronic sequelae that may be irreversible. This is not acceptable. Why? Because it is not acceptable to watch people suffer and potentially die from infections that are treatable just because the medications are not available due to manufacturing issues and stockpiling.

Lastly, as we start to see a rise in Lyme disease, not only will we have great difficulty with treatment, but I suspect diagnosis may be delayed due to the overlap in symptoms with COVID-19 in the early stages. I urge everyone to be on alert. Check yourself, your children and your pets for ticks. Use appropriate insect repellants but also use caution avoiding heavily wooded areas, areas with high grass and shrubs, leaf piles and wood piles, and other high-risk areas. Alert your doctor if you get a tick bite or develop fever, achiness, headache or other non-specific symptoms. Of course, it could be COVID-19, but it could also be something else.

THE SOLUTION:

We cannot ignore other potentially dangerous conditions and we must not assume that everything is COVID-19. I strongly urge doctors to keep Lyme disease and other tick-borne infections on their differential diagnosis list. While our country, our scientists and our medical professionals work towards control of the COVID-19 pandemic, let us not forget the silent pandemic of Lyme disease.

Lyme disease is found in every state in the U.S. and every continent in the world, except for Antarctica. The incidence and prevalence of the infection increases each year. Based on the assumption that at least 20% of patients experience treatment failure, we currently have over 1 million people in the U.S. with chronic Lyme disease and this does not include many who are undiagnosed, yet suffer the debilitating consequences.

Despite these growing numbers, naysayers still believe that Lyme is very easily treated and not a significant public health problem. That couldn’t be further from the truth. There are very loud voices championing Lyme disease research and education and yet their voices are muffled by those that don’t recognize that we are dealing with a global health issue that is expanding its reach every year.

Once we gain control over the immediate COVID-19 pandemic, I truly hope we use what we have learned and apply the same sense of medical urgency to Lyme disease and other tick-borne infections.

The destruction of Covid-19 is visible. The destruction and multisystemic effects of lyme disease is not. Just because you cannot see the destruction, does not mean it is not there. It is time we treat invisible illness with as much urgency as we treat visible illness in this country.

The economic impact of the effects of chronic lyme disease.

Lyme disease costs approximately $1.3 billion each year in direct medical costs in the United States, but this is likely a gross underestimate that doesn’t consider the full economic and societal costs. Some have proposed the cost to be closer to the $50- to $100-billion-dollar range. The numbers are even more staggering when we look at individual patients and what the cost is to them, not just financially but also in quality of life.

On average, Lyme patients might see 10-30 or more doctors before being properly diagnosed. Some of the costs might initially be covered by their insurance but as time goes on and their condition worsens, patients often need to do more extensive testing and see doctors outside their insurance plan, who have a specific interest and passion in treating complex, chronically ill patients. Lyme disease is a complex, multisystemic illness that is difficult to detect due to the lack of sensitive test and the way it evades the immune system, wreaking havoc before it’s discovered. The current medical model does not allow doctors to spend enough time with patients, which leads to misdiagnoses and even false labeling, that is not easily reversed.

Because the symptoms are so diverse and involve so many different parts of the body, including the nervous system and the brain, doctors have a hard time piecing the symptoms together.

Unfortunately, these patients are at risk for being labeled with a functional psychiatric disorder like anxiety, depression or OCD, and are often sent for psychiatric evaluation, which further delays them from receiving proper treatment for Lyme disease. We know that Lyme can cause neuropsychiatric illnesses, but this needs to be recognized as a consequence of the Lyme and treated as such.

_____________________

**Comment**

This article was written before the good news of successful COVID treatments.  HCQ, zinc, azithromycin, and Ivermectin have all shown fantastic results, along with numerous natural treatments.  Doctors have been writing about their clinical success using these treatments for months and months but now have clinical studies supporting their success.

The ‘powers that be’ continue to malign, deny, and censor this important information.
The reason for this censorship is quite simple.  Vaccines are not needed if treatments exist.

Tuttle’s Response to HHS Request for Information: “Any Published Evidence Identifying Persistent Infection After Extensive Antibiotic Treatment Has Been Completely Ignored”

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/29172177?

HHS Request for Information

JUN 7, 2021 — 

Please see below my submission to HHS Request for Information: (Deadline June 11th)

How to submit a comment:  https://www.federalregister.gov/documents/2021/04/27/2021-08167/request-for-information-rfi-developing-the-national-public-health-strategy-for-the-prevention-and

June 6, 2021

Developing the National Public Health Strategy for the Prevention and Control of Vector-Borne Diseases in Humans

It was once believed that rifampin was curative in treating Brucellosis but when symptoms returned doxycycline was added to the mix and when that too failed a third antibiotic, streptomycin was added to the current treatment regimen. [1] [2]

In 1985 the worldwide incidence of leprosy was 6,000,000. In 2018, it was 208,619. The only thing that changed was the addition of rifampin to dapsone in the treatment of the disease. Rifampin was added to dapsone because the M leprae were becoming resistant and it was a new antibiotic at that time.

Treatments for multidrug-resistant tuberculosis have been introduced (bedaquiline and delamanid) with more in the pipeline. [3]

A new treatment for recurrent Clostridium difficile was recently studied (bezlotoxumab) for reducing the risk of a repeat infection. [4]

In contrast, oral amoxicillin or doxycycline remains the treatment of choice for treating Lyme disease for over thirty years regardless if debilitating symptoms return. Since 1977 Dr. Allen Steere knew that these antibiotics were not effective for all patients [5] but there has been no change in treatment or research to find more effective ways to eradicate the infection in all stages of disease.

To my knowledge, a “Federal Working Group” was never established for brucellosis, leprosy, tuberculosis or C. difficile but then again there was no rush to create a vaccine as there was with Lyme disease. It would appear that a chronic relapsing seronegative disease did not fit the vaccine model.

All patients in the 2018 Middelveen et al pilot study were culture positive for infection (genital secretions, skin and blood) even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics. [6]

Here’s what researchers at Johns Hopkins and Northeastern are saying: [7]

“Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease.”

Dr. Brian Fallon of Columbia University recently published his findings of autopsy specimens from a patient previously treated for Lyme disease. Persistent infection with the Lyme disease spirochete was identified in the brain of the Lyme patient who died with a diagnosis of Lewy body dementia. [8]

Any published evidence identifying persistent infection after extensive antibiotic treatment has been completely ignored. Please see my letter to the editor of the BMJ published June 2020 for examples. [9] The research to find a cure for this antibiotic resistant/tolerant superbug has been denied for decades as the co-chair of the Tick-Borne Disease Working Group, Dr David Walker calls persistent infection after extensive antibiotic treatment a “religious belief” [10] This partnership to deny chronic Lyme disease has left hundreds of thousands if not millions around the globe in a debilitated state.

For three decades now patient testimony all across America (and around the globe) has been describing a disease that is destroying lives, ending careers while leaving its victim in financial ruin.

Priority # 1 for Lyme disease:

Establish a Manhattan Project to Find a Cure for this antibiotic resistant/tolerant superbug and elevate Lyme to Highest Alert at the CDC while recognizing the disabling stage of Lyme disease.

Respectfully submitted,

Carl Tuttle
Hudson, NH

Member of Governor Chris Sununu’s Lyme Disease Study Commission
http://www.gencourt.state.nh.us/statstudcomm/details.aspx?id=1515&rbl=1&txtbillnumber=hb490

Cc: All members of the New Hampshire Lyme Disease Study Commission

References: 

[1] Chronic Brucellosis and Persistence of Brucella melitensis DNA
https://www.ncbi.nlm.nih.gov/pubmed/?term=Chronic+Brucellosis+and+Persistence+of+Brucella+melitensis+DNA

[2] Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.
https://www.ncbi.nlm.nih.gov/pubmed/25246401

[3] Global Introduction of New Multidrug-Resistant Tuberculosis Drugs—Balancing Regulation with Urgent Patient Needs
https://wwwnc.cdc.gov/eid/article/22/3/15-1228_article

[4] New C.diff treatment reduces recurrent infections by 40%
https://www.sciencedaily.com/releases/2017/01/170126081724.htm

[5] Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. 1977
https://pubmed.ncbi.nlm.nih.gov/836338/

Excerpt:

“The best treatment for this illness is not clear. Some physicians have reported that penicillin or tetracycline results in disappearance of the skin lesion (41,42), but others find antibiotics ineffective. Four of the patients with expanding skin lesions received penicillin but still developed arthritis.” 

[6] Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
http://www.mdpi.com/2227-9032/6/2/33

[7] A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
https://pubmed.ncbi.nlm.nih.gov/27242757/

[8] Detecting Borrelia Spirochetes: A Case Study With Validation Among Autopsy Specimens
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141553/

[9] Lyme borreliosis: diagnosis and management
https://www.bmj.com/content/369/bmj.m1041/rr-1

[10] Public comment: Does that sound like a religious belief, Dr. Walker?
https://www.lymedisease.org/tuttle-comment-tbdwg-nov17/

Request for Information (RFI): Developing the National Public Health Strategy for the Prevention and Control of Vector-Borne Diseases in Humans
The development of a national strategy on vector-borne diseases including tickborne diseases was…